علاج مرض القلب الإقفاري في حالات انخفاض ضغط الدم وبطء القلب

References

DOI: 10.1093/eurheartj/suaa060

The guidelines suggest it if the symptoms are not well-controlled with BB, calcium channel blockers, or nitrates or if hypotension and bradycardia limit the use of these drugs (Class IIa indication of European and American guidelines).

The most recently introduced drugs, ranolazine and ivabradine, have not been shown to modify the patients' prognosis and their adoption in clinical practice has been anything but disruptive, however, they are an important resource in hypotensive and bradycardic patients.

This drug does not affect heart rate or blood pressure.

In the treated group a reduction in the frequency of angina attacks and a reduction in the use of sublingual nitrates was highlighted.